Insulin-loaded polymeric mucoadhesive nanoparticles: development, characterization and cytotoxicity evaluation by Gatti, Tiago Henrique Honorato et al.
Braz. J. Pharm. Sci. 2018;54(1):e17314 Page 1 / 10
Brazilian Journal of 
Pharmaceutical Sciences
http://dx.doi.org/10.1590/s2175-97902018000117314
A
rt
ic
le
*Correspondence: M. Chorilli. Faculdade de Ciências Farmacêuticas, De-
partamento de Fármacos e Medicamentos, Universidade Estadual Paulista 
(UNESP). Rodovia Araraquara-Jau, km. 1, 14801-902, Araraquara, São Paulo, 
Brasil. Telefone.: +55 16 3301 6998. E-mail: chorilli@fcfar.unesp.br / J. O. 
Eloy: josimar.eloy@gmail.com
# Both authors equally contributed to this paper
Insulin-loaded polymeric mucoadhesive nanoparticles: 
development, characterization and cytotoxicity evaluation
Tiago Henrique Honorato Gatti1#, Josimar Oliveira Eloy1#*, Leonardo Miziara Barboza Ferreira1, 
Isabel Cristine da Silva2, Fernando Rogério Pavan2, Maria Palmira Daflon Gremião1, Marlus Chorilli1*
1School of Pharmaceutical Sciences, UNESP – São Paulo State University, Campus Araraquara, Department of Drugs and 
Medicines, Araraquara, SP, Brazil, 2School of Pharmaceutical Sciences, UNESP – São Paulo State University, Campus 
Araraquara, Department of Biological Sciences, Araraquara, SP, Brazil
Mucoadhesive nanoparticles are particularly interesting for delivery through nasal or pulmonary routes, 
as an approach to overcome the mucociliary clearance. Moreover, these nanoparticles are attractive for 
peptide and protein delivery, particularly for insulin to treat diabetes, as an alternative to conventional 
parenteral administration. Thus, chitosan, a cationic mucoadhesive polysaccharide found in shells of 
crustaceans, and the negatively-charged dextran sulfate are able to form nanoparticles through ionic 
condensation, representing a potential insulin carrier. Herein, chitosan/dextran sulfate nanoparticles at 
various ratios were prepared for insulin loading. Formulations were characterized for particle size, zeta 
potential, encapsulation efficiency, scanning electron microscopy, differential scanning calorimetry, and 
in vitro drug release. Moreover, the interaction with mucin and the cytotoxicity against a lung cell line 
were studied, which altogether have not been addressed before. Results evidenced that a proper selection 
of polyelectrolytes is necessary for smaller particle size formation and also the composition and zeta 
potential impact encapsulation efficiency, which is benefited by the positive charge of chitosan. Insulin 
remained stable after encapsulation as evidenced by calorimetric assays, and was released in a sustained 
manner in the first 10 h. Positively-charged nanoparticles based on chitosan/dextran-sulfate at the ratio 
of 6:4 successfully interacted with mucin, which is a prerequisite for delivery to mucus-containing 
tissues. Finally, insulin-loaded nanoparticles displayed no cytotoxicity effect against lung cells at tested 
concentrations, suggesting the potential for further in vivo studies.
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INTRODUCTION
Diabetes mellitus represents the most prevalent 
metabolic disorder nowadays, with 345 million people 
affected worldwide (Sah et al., 2016). Furthermore, it is 
believed that in 2030 the number of patients will raise up 
to 552 million, which can be considered a threat for public 
health (Whiting et al., 2011). A major concern is that life 
expectancy is reduced by many years in patients with type 
1 or 2 diabetes. The therapy involves different approaches, 
including diet, physical exercise and hypoglycemic drugs. 
For Type 1 diabetes patients, due to insufficient insulin 
production, exogenous hormone is needed (Salvioni et 
al., 2016). The peptide insulin is the most effective drug 
for diabetes treatment, with high specificity and activity 
(Fonte et al., 2014). However, the most common route for 
insulin administration, the parenteral route, faces many 
hurdles, such as the difficulty of achieving a normal pattern 
of nutrient-related and basal insulin. Furthermore, the 
subcutaneous injection, which must pass through the skin 
for systemic effect, results in considerable tissue trauma 
and pain (Sintov, Levy, Botner 2010; Li et al., 2017). 
Considering the instability of peptides, for an effective 
therapeutic outcome, they should be protected against 
degradation. Therefore, the use of appropriate carriers is 
needed for effective delivery (Huang et al., 2009). Strategies 
have been directed to improve insulin delivery by the use of 
colloidal systems, possessing diameter less than 1 µm (Diop 
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et al., 2015). Among these colloidal carriers, nanoparticles 
are able to prevent peptide degradation and promote 
sustained release, with consequent better therapeutic 
response and patient compliance (Zheng et al., 2013; 
Giovino et al., 2012). Thus, nanoparticles have been used for 
nasal or pulmonary routes for delivery of insulin, avoiding 
the problems associated with the parenteral administration. 
For instance, the nasal route of delivery has been exploited 
for needle-free systemic delivery of a wide range of drugs, 
including small molecules, proteins and peptides, such as 
insulin. Noteworthy, intranasal drug delivery offers many 
advantages, such as the large absorptive area with high 
vascularization, avoiding the first-pass liver metabolism 
(Casettari, Illum 2014; Zhang et al., 2008). Furthermore, the 
pulmonary route is also interesting for drug delivery, such 
as insulin, due to the large surface area for drug absorption, 
which can also benefit from mucoadhesive formulations, 
especially those capable of overcoming the mucociliary 
clearance (Jain et al., 2008; Alpar et al., 2005). 
Bioadhesive polymers, for example chitosan and 
alginate, are polysaccharides employed in nanoparticle 
formation owing to their mucoadhesive properties, 
through the interaction with the negatively charged mucin 
(Andreani et al., 2015). Chitosan, a cationic polysaccharide 
with glucosamine and N-acetylglucosamine, is derived 
from the deacetylation of chitin, found in shells of 
crustaceans and is soluble in mildly acidic aqueous 
solutions. Chitosan presents many advantages, such as 
its availability and biocompatibility. Owing to its many 
advantages, chitosan has been used as a drug delivery 
carrier, including for controlled release of insulin. Very 
interestingly, chitosan hydration and gel formation 
allow to prolong release of the drug at the administration 
site (Huang et al., 2009; Ravindranathan et al., 2016; 
Szekalska et al., 2016). Moreover, chitosan is able to 
disrupt epithelium tight junctions, due to interaction of 
protein Kinase C (Smith, Dornish, Wood, 2005). Although 
polyelectrolyte nanoparticles based on chitosan have been 
previously reported for insulin loading, to our knowledge, 
our paper is the first to address the in vitro mucoadhesion 
or cytotoxicity on lung fibroblast cells of chitosan/sulfate 
dextran nanoparticles loaded with insulin. Altogether, 
these are important preliminary parameters regarding 
pulmonary or nasal delivery of insulin from nanoparticles 
(Sarmento, Veiga, Ferreira, 2006; Mao et al., 2006; Lopes 
et al., 2016). Recently, the effect of albumin coating on 
chitosan/dextran-sulfate nanoparticles was investigated. 
The authors aimed to protect insulin from degradation in 
the acidic or intestinal environments considering the oral 
drug delivery. Unlike our study, the authors employed the 
nanoemulsion method for nanoparticle preparation, using 
surfactants for stabilization, such as sorbitane monooleate 
and Poloxamer 188 (Lopes et al., 2016).
Thus, the purpose of this work was to develop 
and characterize formulations based on chitosan/
dextran-sulfate, intended for mucoadhesion of insulin, 
potentially applied for nasal or pulmonary delivery. We 
investigated the chitosan/dextran-sulfate ratio influence 
on encapsulation efficiency, zeta potential and particularly 
on particle size. Additionally, we studied the in vitro 
drug release using dialysis membrane and the interaction 
between the formulation and insulin through thermal 
analysis employing the NanoDSC equipment. Noteworthy, 
the complexation with mucin for in vitro mucoadhesive 
evaluation and the cytotoxicity of formulations against 
MCR-5 fibroblast lung cells, both important parameters 
prior to in vivo application, were addressed.
MATERIAL AND METHODS
Material
Dextran sulfate sodium salt (average MW˃500,000 
Da), chitosan (low molecular weight. MW, ranging 
from 50,000 to190,000 Da), resazurin, porcine stomach 
mucin, type II, and doxorubicin were purchased from 
Sigma-Aldrich. Novolin® R human insulin was obtained 
from Novo Nordisk. Glacial acetic acid was supplied by 
QUEMIS. 12-14 kDa MWCO (molecular weight cut-
off) cellulose dialysis membranes were obtained from 
Fisherbrand. MRC-5 cells were supplied by American 
Type Collection. DMEM medium, fetal bovine serum 
(FBS) and antibiotic/antimicotic solution were purchased 
from Gibco. 0.25% trypsin/EDTA was supplied by 
Vitrocell. Ultra-purified water was obtained from Milli®Q 
Plus System (Millipore).
Methods
Development of insulin-loaded nanoparticles
The nanoparticles were synthesized by the 
combination of two polymers, a polycation, chitosan 
(low molecular weight. MW, ranging from 50,000 to 
190,000 Da), and a polyanion, dextran-sulfate sulfate 
sodium salt (average MW˃500,000 Da) (Sarmento, Veiga, 
Ferreira, 2006). The total polymer concentration, 0.5, 
1.0, and 1.5 mg/mL in aqueous solution, pH 4,6, and the 
chitosan/dextran-sulfate ratio, 1:9, 2:8, 3:7, 4:6, 1:1, 6:4, 
7:3, 8:2 and 9:1, were investigated. Nanoparticles were 
obtained after dropwise addition of chitosan solution to 
dextran-sulfate solution under vortex stirring for 15 min. 
Insulin was loaded in the formulations at 500 µg/mL 
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concentration. For this purpose, the peptide addition order 
was studied, i.e, after the formation of the nanoparticle, 
or onto chitosan solution, or onto dextran sulfate solution, 
prior to the nanoparticle formation. 
Physicochemical characterization of insulin-loaded 
nanoparticles
•	 Particle size
Particle size was measured through the dynamic 
light scattering (DLS) technique at 633 nm, using the 
angle of 173°, at room temperature (Zetasizer Nano-Zs, 
Malvern Instruments). Samples were diluted with water 
before analysis. Measurements were done in triplicate with 
10 determinations for each one.
•	 Zeta potential 
Zeta potential was measured through electrophoretic 
mobility of particles. Analysis was carried out using 
the DLS equipment (Zetasizer Nano-Zs, Malvern 
Instruments). Samples were diluted with water before 
analysis. Measurements were done in triplicate with 10 
determinations for each one.
•	 Encapsulation efficiency 
The encapsulation efficiency (EE) was determined 
by ultraviolet-visible (UV) spectroscopy, with insulin 
measurement at 270 nm, following equation 1. For 
separation of insulin-loaded nanoparticle and free insulin, 
centrifugation was performed at 14.000 rpm for 10 min. 
Free insulin corresponded to the insulin in the supernatant 
fraction (Sarmento, Veiga, Ferreira 2006).
  (Equation 1)
•	 Differential Scanning Calorimetry (DSC)
DSC analysis was carried out using the Nano DSC 
equipment, TA Instruments. Samples were degassed 
under vacuum before loading into the capillary cells 
composed by platinum and heated from 0 to 100°C, at a 
rate of 2°C/min. The samples scans were subtracted from 
ultra-purified water reference scan. Data analyses were 
carried out using the Nanoanalyse software (Andreani et 
al., 2015).
•	 Morphology by Scanning Electron Microscopy 
(SEM)
SEM morphology was evaluated using a JEOL 
JSM-7500F microscope. For that, a drop of nanoparticle 
dispersion was applied to the carbon grid, dried and gold 
coated under vacuum. Photomicrographs were obtained 
using 2.00 kV electron beam.
In vitro insulin release
Experiments were done in sextuplicate at 32 °C 
using a Franz diffusion cell system, at 400 rpm. Cellulose 
acetate membranes (12-14 kDa MWCO) were placed 
between the donor and the receptor compartments, the 
latter filled with deionized water (7 mL), following a 
method previously described, with modifications (Liu et 
al., 2012). Samples in the receptor compartments were 
collected in predetermined intervals, with replacement 
of fresh medium. Released insulin was quantified in the 
receptor compartment, using a spectrophotometric method 
at 270 nm, using an insulin standard curve.
In vitro mucin/ nanoparticle interaction
Blank nanoparticles were incubated with mucin 
solution (2 mg/mL) at different mucin/nanoparticles ratios, 
vortexed and incubated under stirring at 37 °C for 30 min 
(Andreani et al., 2015). Afterwards, the dispersions were 
centrifuged for 10 min at 10000 rpm and the supernatant 
was used for mucin UV spectrophotometric quantification 
at 280 nm (Boya et al., 2017). Mucin adsorbed on 
samples was determined by the difference between the 
final and initial mucin concentration after incubation and 
centrifugation.
Cell culture
MRC-5 (normal lung fibroblast cells) cell line was 
obtained from the American Type Culture Collection 
(Manassas, VA, USA) and incubated in DMEM medium 
supplemented with 10% FBS and 1% penicillin (100 U/
mL)–streptomycin (100 µg/mL). Cells were maintained 
in a humidified environment at 37 °C with 5% CO2 and 
sub-cultured twice per week.
Cytotoxicity tests
A resazurin reduction assay was used to investigate 
cytotoxicity on MRC-5 cells. The assay is based on 
reduction of the indicator dye, resazurin, to the highly 
fluorescent resorufin by viable cells. Nonviable cells 
rapidly lose the metabolic capacity to reduce resazurin 
and thus do not produce a fluorescent signal. Briefly, the 
cells were detached by treatment with 0.25% trypsin/
EDTA (VitroCell, Brazil) and 2.5 x 104 cells were placed 
on each well of a 96-well cell culture plate (Costar, 
USA) in a total volume of 100 µL. Cells were allowed 
to adhere overnight and then were treated with different 
T. H. H. Gatti, J. O. Eloy, L. M. B. Ferreira, I. Silva, F. Pavan, M. P. D. Gremião, M. Chorilli
Braz. J. Pharm. Sci. 2018;54(1):e17314Page 4 / 10
concentrations of drugs. After 24 h incubation in the 
presence of the compounds, the medium was removed and 
50 µL resazurin (Sigma-Aldrich, Germany) 0.01% w/v 
in DMEM, was added to each well and the plates were 
incubated at 37 °C for 3 h.
The fluorescence was measured on Biotek Synergy 
H1 plate reader (Biotek, Winooski, VT) using an excitation 
wavelength of 530 nm and an emission wavelength of 590 
nm. Untreated cells constituted the negative control (viable 
cells), and cells treated with doxorubicin at 100 nmol 
(Sigma-Aldrich, St. Louis, MO, USA) constituted the 
positive control (dead cells). All the tests were performed 
in three independent assays. Graphs were expressed 
as lethality (%). The IC50 values represent the samples 
concentrations required to inhibit 50% of cell proliferation 
and were calculated using the GraphPad Prism® 5 (Version 
5.01, GraphPad Software, Inc., USA)
RESULTS AND DISCUSSION 
Polyelectrolyte complexes can be synthesized in 
aqueous solutions through ionic interactions between 
polyelectrolyte compounds with opposite charges, 
particularly in low ionic strength media. Critical 
coagulation concentrations of 0.12 and 0.09 M (with 
sodium chloride) for cationic and anionic particles has 
evidenced a mostly electrostatic stabilization (Schatz 
et al., 2004a). Furthermore, dissociation of complexes 
decreases with increased salt concentration, which is 
likely due to the result of reduced attraction between the 
oppositely charged polyelectrolytes (Mao et al., 2006). For 
complexation with chitosan, dextran sulfate is the most 
widely employed polysaccharide, due to many advantages, 
such as the low price, ease availability and also because 
of the strong ionic interaction between its sulfate group 
and the ammonium groups of chitosan (Delair, 2011). 
Nanoparticles have been shown to be formed through the 
coacervation between chitosan and dextran sulfate, with 
application for the loading of proteins and peptides, such as 
insulin (Sarmento, Veiga, Ferreira, 2006). Furthermore, the 
ionic coacervation is environment friendly and the results 
obtained over the years with nanoparticles based on chitosan 
and dextran sulfate underline the high potential of this 
strategy for development of human medicine (Delair, 2011). 
Figure 1 summarized the results of particle size 
obtained with different nanoparticle compositions, 
containing decreasing total excipient concentrations, 
prepared at varied chitosan/dextran sulfate ratios. It 
became evident that unless prepared with only chitosan 
or dextran sulfate, nanoparticles composed by the mixture 
of the two polyelectrolytes were not strongly affected by 
the ratio between the components. Conversely, Shatz and 
co-workers(2004b) observed that higher dextran sulfate 
concentrations led to increased particle size, whereas 
higher concentration of chitosan favored the formation 
of more particles, without influencing particle size. 
However, the nanoparticles were prepared differently 
compared to the protocol employed herein, which could 
potentially influence the particle size results obtained. It 
was reported the use of a purification step of nanoparticles 
by centrifugation for 30 min at 8000-12000 rpm, with 
resuspension in a minimum volume of deionized water, in 
order to avoid the adsorption of free polymer onto particle 
surface. Also, we need to consider that the insulin presence 
in the nanoparticles reported in our paper could have 
changed the behavior observed in the paper by Schatz et 
al.(2004b), who did not encapsulate the peptide. 
FIGURE 1 - Study of the influence of total excipient concentration 
(A = 1.5 mg/mL, B = 1.0 mg/mL and C = 0.5 mg/mL) and the 
ratio of dextran sulfate/chitosan (open circle) on particle size 
(gray closed circle).
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Noteworthy, herein we found that the total polymer 
concentration affected the particle size. Chitosan and 
dextran sulfate concentrations equivalent to 0.5, 1.0 and 
1.5 mg/mL resulted in mean particle size values of all 
formulations at 605.06, 816.30 and 859 nm, respectively. 
Therefore, the total polymer concentration chosen 
for further studies was 0.5 mg/mL and the selected 
formulations were prepared employing chiton/dextran 
sulfate at the ratios of 1:9, with particle size of 432.2 
nm and zeta potential of -54.7±0.458 mV, due to the 
negatively charged dextran sulfate in excess, and another 
composition with chitosan in excess, at the ratio of 6:4, 
generating particle size of 320.55 nm and zeta potential 
of 38.6±0.1 mV. Interestingly, particle size achieved with 
this latter formulation developed herein is smaller than 
the chitosan/dextran sulfate particles previously reported 
for insulin loading, which ranged from 489 ± 11 to 1612 
± 248 (Sarmento, Veiga, Ferreira, 2006). The reduction 
of particle size is important for further applications of 
the nanoparticles developed herein. For instance, several 
types of nanoparticles have been employed for lung drug 
delivery with improved uptake and action and it is known 
that smaller nanoparticles traverse the surfactant layer 
more efficiently than larger nanoparticles probably due 
to minimal steric hindrance (Iyer, Hsia, Nguyen, 2015).
The encapsulation efficiency of insulin in 
nanoparticles was low, equivalent to 9.73 and 16.67%, 
for the chitosan:dextran sulfate (1:9) and chitosan:dextran 
sulfate (6:4) formulations, respectively, in disagreement 
with previous observations of high encapsulation 
efficiency of insulin in formulations prepared with excess 
dextran sulfate (Sarmento, Veiga, Ferreira, 2006). In order 
to circumvent this drawback, it was attempted to add 
insulin in the chitosan solution or in the dextran sulfate 
solution, prior to the nanoparticle coacervation, albeit 
even lower encapsulation efficiency values were achieved 
(data not shown). Within this context, Mao and co-workers 
proved that the complexation between chitosan and insulin 
is pH dependent, and it is favored above the critical pH of 
6.0 (Mao et al., 2006). On the other hand, in that paper, 
the formulation was different than the one reported herein, 
because it was not used dextran sulfate, a counterion 
commonly employed to form nanoparticles though 
ionic complexation (Chaiyasan, Srinivas, Tiyaboonchai 
2013). Furthermore, the pH requirement for nanoparticle 
formation when dextran-sulfate is used in combination 
with chitosan is different, considering that Sarmento, Veiga 
and Ferreira (2006) prepared insulin-loaded nanoparticles 
in pH below 5.0 with excellent encapsulation efficiency, 
higher than 85%. However, we need to consider that while 
Sarmento, Veiga and Ferreira (2006) used insulin at a 
concentration of 58.33 µg/mL, whereas we employed a 
higher drug concentration of 500 µg/mL, which could have 
affected the encapsulation efficiency due to insulin excess. 
Hence, the insulin concentration of our nanoparticles 
was almost 10 times higher, which could compensate 
the low encapsulation efficiency of insulin. Finally, the 
low encapsulation of hydrophilic drugs in polymeric 
nanoparticles has been commonly reported and remains 
a challenge during formulation development (Vrignaud, 
Benoit, Saulnier, 2011). Therefore, the low encapsulation 
efficiency shortcoming should be addressed in more details 
in future studies.
The evaluation of the morphology properties of the 
formulations was conducted by SEM. Photomicrographs 
shown in Figure 2 evidenced the aggregate nature of 
spherical chitosan/dextran sulfate (1:9) nanoparticles, 
unlike with the chitosan/dextran sulfate (6:4) formulation, 
which did not present defined structure, probably to excess 
adhesive chitosan which resulted and highly aggregated 
formulation.
DSC experiments can reveal structural changes 
of proteins when incorporated into delivery systems 
and was therefore carried out to elucidate the thermal 
events of insulin-loaded nanoparticles (Jorgensen et al., 
2004). All the endothermic and exothermic insulin peaks 
were indicated with arrows. Figure 03 revealed a minor 
endothermic peak centered at 77°C (∆H = 0.04 kJ mol-1) 
followed by a major exothermic peak at 85.30 °C (∆H = 
0.4 kJ mol-1) for insulin, which has been already reported 
FIGURE 2 - Scanning electron microscopy (SEM) of A 
(dextran sulfate), B (chitosan), C (chitosan/dextran sulfate 
(1:9) nanoparticles) and D (chitosan/dextran sulfate (6:4) 
nanoparticles).
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for dendrimer-loaded insulin (Nowacka et al., 2016). The 
sequence of endothermic followed by exothermic peak 
could be correlated with protein denaturation followed 
by aggregation (Sarmento, Veiga, Ferreira, 2006). It is 
possible that insulin once denatured can expose interaction 
sites able to produce insulin-insulin linkages and, 
therefore, promote the formation of peptide aggregates 
(Gibson, Murphy, 2006). 
The pattern of endothermic event followed by 
exothermic event was also observed for insulin loaded 
in the two compositions of chitosan/dextran sulfate 
nanoparticles studied. However, we can observe that 
the two types of nanoparticles show opposite behavior 
regarding the location and shape of the peaks. While 
chitosan/ dextran sulfate 1:9 nanoparticles had a shift of 
the endothermic peak to lower temperature (~ 67 °C, ∆H = 
0.7 kJ mol-1) and a shift and broadening of the exothermic 
peak to higher temperature (~ 88°C, ∆H = 1.0 kJ mol-1), 
chitosan/ dextran sulfate 6:4 nanoparticles had a shift 
of both endothermic and exothermic peaks to higher 
temperatures, 88 °C (∆H = 0.3 kJ mol-1) and 94.5 °C (∆H 
= 0.6 kJ mol-1) respectively. These results suggested that 
insulin was, at least partially, protected from degradation 
in the cationic nanoparticle (chitosan: dextran sulfate, 
6:4), which also presented the highest degree of insulin 
encapsulation.
In vitro drug release has been regarded as a parameter 
to assess formulation safety and efficacy, being used to 
reflect the in vivo behavior (Souza, 2014). Nanoparticles 
may serve as a platform for sustained release of drug, 
achieving a prolonged effect due to slow drug release, 
with several advantages, including lesser frequency of 
administration, reduced side effects, with consequent 
better patient compliance (Natarajan et al., 2014). Herein, 
the in vitro release studies using a dialysis membrane 
showed that both formulations presented similar release, 
with a slow pattern in the first 10 h, then reaching the 
plateau (Figure 4). Sarmento, Veiga and Ferreira (2006) 
obtained similar results in their evaluation of chitosan/
dextran sulfate nanoparticles for oral delivery, however 
plateau was reached around 5 h in pH 6.8 release medium. 
Therefore, the nanoparticles reported herein seem to 
present more sustained insulin release.
The process of drug release is complex and 
influenced by the physicochemical properties of the 
drug, the characteristics of the matrix and the release 
environment. Solute diffusion, polymeric material 
swelling and degradation have been suggested as the main 
factors explaining drug release. In general, mathematical 
models give insight into the release mechanism, revealing 
the process kinetics. Insulin release kinetics from the 
negatively charged nanoparticle corresponded to the 
Weibull model and is related to Fick’s law diffusion, related 
to drug diffusion. On the other hand, the positively charged, 
chitosan/dextran sulfate (6:4) nanoparticle released insulin 
according to the Peppas model, an anomalous non-Fickian 
release kinetics, related to polymeric swelling (Grassi, 
Grassi, 2005). Hence, the chitosan/dextran sulfate ratio 
affected the kinetics mechanism of insulin release.
Herein, it was shown the successful complexation 
with mucin, which was better for the chitosan/dextran 
sulfate (6:4) formulation, with maximum 66.72% 
interaction, compared to 34.70% interaction achieved 
with the chitosan/dextran sulfate (1:9) formulation, at 
0.5 mucin/nanoparticle ratio (Figure 5). It is important to 
consider that the formulation prepared with more chitosan 
FIGURE 4 - In vitro release study of insulin-loaded nanoparticles.
FIGURE 3 - Dynamic scanning calorimetry (DSC) curves of 
insulin (A), chitosan/dextran sulfate (1:9) nanoparticle (B) and 
chitosan/dextran sulfate (6:4) nanoparticle (C), heated from 0 
to 100 °C.
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presents positive zeta potential, and it is known that 
positive surface has an important role on mucoadhesion, 
since the positive charge of nanoparticles can interact with 
the negatively charged sialic groups of mucin (Barbi et al., 
2015). The high interaction with mucin presented by the 
positively charged nanoparticle might be an indicative of 
promising nasal or pulmonary applications. 
 Furthermore, it is interesting to note that the 
positively charged formulation interaction with mucin 
decreased in the presence of higher mucin/nanoparticle 
ratios, whereas the behavior is opposite for the negatively 
charged formulation, indicating that the electrostatic 
contribution for interaction decreases when the formulation 
is present in lower concentrations. On the highest mucin/
nanoparticle ratio, the percentage interaction with mucus 
is similar for the two formulations, around 40%. It should 
be noted, on the other hand, that other parameters affect 
interaction between nanoparticles and mucus, for instance, 
buffer conditions such as pH and ionic strength (Lieleg, 
Vladescu, Ribbeck, 2010). Nanoparticles not only must 
be mucoadhesive, but also pass through mucus barrier to 
reach circulation. For mucus penetration, nanoparticles 
must be small enough to avoid steric inhibition by 
dense fiber mesh. In this context, it has been previously 
demonstrated that nanoparticles as large as 500 nm can 
rapidly diffuse though physiological human mucus (Lai et 
al., 2007). Therefore, the nanoparticles developed herein 
might have potential for mucus penetration.
The nasal or pulmonary routes represent promising 
alternative delivery sites, offering the possibility to 
avoid the first-pass metabolism enabling direct blood 
drug absorption. Noteworthy, the pulmonary route is 
particularly attractive for protein and peptide delivery 
owing to the large absorptive surface area with the thin 
alveolar mucosal membrane (Ahmed, Aljaeid, 2016). 
Albeit promising for the delivery of several drugs, these 
routes present the challenge of the mucociliary clearance 
(Alpar et al., 2005). Thus, mucoadhesive formulations 
emerged as an alternative to address this issue (Barbi 
et al., 2015). In this context, chitosan is one of the most 
employed biomaterials for the purpose of mucoadhesion, 
due to electrostatic interactions of cationic chitosan 
with negatively charged mucin (Sogias, Williams, 
Khutoryanskiy, 2008). Regarding insulin effect following 
in vivo administration, chitosan gels have caused increase 
in insulin absorption and reduction of glucose level after 
nasal administration (Varshosaz, Sadrai, Heidari, 2006). 
Another paper reported the preparation of a dry powder 
system consisting of microencapsulated insulin-loaded 
chitosan nanoparticles, which were evaluated in vivo in rats 
and resulted in deep lung deposition with pronounced and 
prolonged hypoglycemic effect (Ahmed, Aljaeid, 2016). 
On the other hand, chitosan-sulfate dextran is a novel 
approach for insulin delivery to the nasal or pulmonary 
routes and presents potential for future evaluation.
Toxicology of nanoparticles is an important aspect 
to be evaluated before clinical application. Indeed, 
cytotoxicity studies have been widely employed as 
part of this evaluation (Yildirimer et al., 2011). In our 
studies, we evaluated the cytotoxicity potential of insulin 
and insulin-loaded nanoparticles against normal lung 
fibroblast cells. This cytotoxicity study showed that all 
nanoparticles had non-inhibitory effect on cells at the 
tested concentrations, with IC50 values greater than 250 
µg mL-1, as depicted in Figure 6, while doxorubicin, 
employed as positive control, presented IC50 at 4.5 µgmL-
1. Hence, the relatively low cytotoxicity of the insulin-
loaded nanoparticles could be attributed to the presence of 
biocompatible polymers, which are responsible for weak 
interactions with the cell membrane (Lopes et al., 2016).
CONCLUSION
In this paper, we reported the development and 
characterization of nanoparticles based on chitosan/
dextran sulfate formed by polyelectrolytes condensation 
for insulin loading. Results demonstrated that the proper 
selection of polyelectrolyte total concentration, along with 
chitosan/dextran sulfate ratio, affected nanoparticles size 
and zeta potential. Although herein nanoparticles were 
able to encapsulate insulin with low efficiency, it was clear 
that positively charged nanoparticles based on chitosan/
dextran sulfate at the ratio of 6:4 better encapsulated the 
peptide compared to the composition at the ratio of 1:9, 
FIGURE 5 - Mucin and insulin-loaded nanoparticles interaction 
study.
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due to excess chitosan. Insulin appeared to be partially 
protected from degradation when encapsulated, according 
to thermal analysis. Interestingly, insulin release from 
nanoparticles was sustained, particularly in the first 10h. It 
was demonstrated the efficient mucus complexation between 
mucin and nanoparticles, especially with the positively-
charged one, which could suggest potential application for 
nasal or pulmonary delivery. Finally, the insulin-loaded 
formulations exhibited no cytotoxicity potential against 
a lung cell line. Taken together, the results shown herein 
evidenced potential for future studies regarding insulin-
loaded chitosan/dextran sulfate nanoparticles for nasal or 
pulmonary delivery, potentially applied to treat diabetes.
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